In the BioHarmony Drug Report Database

"Preview" Icon

Fidaxomicin

Dificid, Dificlir (fidaxomicin) is a small molecule pharmaceutical. Fidaxomicin was first approved as Dificid on 2011-05-27. It is used to treat bacterial infections and pseudomembranous enterocolitis in the USA. It has been approved in Europe to treat clostridium infections. Dificid’s patents are valid until 2034-05-28 (FDA).

 

Trade Name

 

Dificlir
 

Common Name

 

fidaxomicin
 

ChEMBL ID

 

CHEMBL1255800
 

Indication

 

bacterial infections, clostridium infections, pseudomembranous enterocolitis
 

Drug Class

 

Antibiotics (Micromonospora strains)

Image (chem structure or protein)

Fidaxomicin structure rendering